Company record · ABBV · Pharmaceutical Preparations
AbbVie Inc.
The principal financial officer who signed AbbVie Inc.'s latest annual report, the 10-K filed February 20, 2026, is Scott T. Reents.
The record holds the CFO signature on AbbVie Inc.'s 10-K filed February 20, 2026 and no Form 8-K CFO change.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Scott T. Reents |
| Title as printed | Executive Vice President, Chief Financial Officer (Principal Financial Officer) |
| Basis | Verified February 20, 2026: the 10-K signature block (sec.gov) |
Seat timeline
1Every verified record for this seat, newest first, dated as the filing states it.
2026-02-2010-K signature
Scott T. Reents signed the annual report as Executive Vice President, Chief Financial Officer (Principal Financial Officer)
10-K filed February 20, 2026 · sec.gov
“/s/ SCOTT T. REENTS Robert A. Michael Chairman of the Board and Chief Executive Officer (Principal Executive Officer) Scott T. Reents Executive Vice President, Chief Financial Officer (Principal Financial Officer)”
Company
| Ticker | ABBV |
|---|---|
| SEC CIK | 0001551152 |
| Industry (SIC) | Pharmaceutical Preparations (2834) |
| Roster note | The DEF 14A filed 2026-03-23 also names Scott T. Reents alongside a Chief Financial Officer title. |
Same industry on the record
8Other companies the roster files under SIC “Pharmaceutical Preparations”.
Cadrenal Therapeutics, Inc.CVKD
Interim CFO: John P. Sharp · effective June 25, 2026
Petros Pharmaceuticals, Inc.PTPI
Departure disclosed · Robert Weinstein · no successor on the record yet
Actinium Pharmaceuticals, Inc.ATNM
CFO: Matt David, M.D. · effective October 14, 2026
Adial Pharmaceuticals, Inc.ADIL
Departure disclosed · Vinay Shah · no successor on the record yet
BeyondSpring Inc.BYSI
CFO: Na Li · effective July 1, 2026
CalciMedica, Inc.CALC
Departure disclosed · Stephen Bardin · no successor on the record yet
Cue Biopharma, Inc.CUE
CFO: James Ahlers · effective July 30, 2026
Emergent BioSolutions Inc.EBS
Change disclosed, effective January 1, 2027 · incoming: Frank Vargo
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.